Member Info for The_Paladin

“The Quality Director was actually recruited as recently as December 2022,”

I am confused by that Spacman. Richard Francis, SVP, Head of CMC and Quality, was recruited a year earlier when we all thought that Synairgen had a transformative year ahead.

In addition, I am clueless as to any benefit that the CEO’s premature recruitment of executives at around the same time has brought to the company? On that subject, it would be useful to know about the work that is being undertaken by the latest recruits? I know more, via RNS, about their share incentives than their roles.

“Richard Francis joined in September 2021 as Head of CMC, bringing more than 35 years of experience in the development, manufacturing, regulatory approval and commercialization of many biopharmaceutical products including Cablivi®, Orthoclone OKT3®, Remicade®, and ReoPro®.”

91m shares sold in a single transaction @ c. 0.0026p. Ouch!

It doesn’t really matter what any of this board’s contributors are doing with Synairgen stock. There is nothing illegal in day trading or short-term selling. It would be an improvement of this forum if no one mentioned this again.

MrCosts must have climbed out of Aether’s green bin at least fifty times by now, followed closely by Professional. Everyone in my green bin doesn’t get mentioned again, as I don’t read their posts! (Neither of the former two contributors are in it, by the way.)

The only issue for me is that elusive Synairgen RNS, announcing that the company is back on track! I have waited for nearly twenty six months for some news of a trial and it is long overdue as far as I am concerned! What I don’t want is more vague BS from the CEO and his acolytes at the next AGM!

GLALTIs.

“As ever patients is required.”

Excellent pun Tommy. GLALTIs.

Thank you Elsol.

For some of us, who believe in SNG001, and its future as a broad spectrum antiviral treatment, 100p+ is a realisable share price goal. The long silence is just a case of “business as usual” as far as Synairgen is concerned.

However, there has been an expectation of further clinical trialling for well over two years. Provided Synairgen can deliver on that during Q2, 2024, the company will remain on track. We may even experience a share price hike?

A joint statement with a BP company would be an altogether different situation. If the current financial restrictions were removed, our future prospects would be far brighter than seems to be the case today.

Has last week's poster display reappeared online? It was sponsoped by Synairgen, and as it was a repeated in vitro trial of SNG001 with CV-19 variants, presumably it will eventually end up on Synairgen's website? I haven't understood why Amanda Horton's X post with this information was removed? Presumably an UKHSA issue?

This is to be expected. Short term traders will always leap in at a hint of forthcoming positive news. Subsequently, when nothing materialises, they retreat and take their capital elsewhere.

I know of one such retail investor, who has managed to achieve an average profit of £30Kp.a. in recent years, through trading, and with a relatively small capital outlay.

At this point in time, I am regretting my involvement with the AIM market. Too often, the way that these companies treat their investors is nothing short of disgraceful. Perhaps Synairgen may yet surprise us despite the lack of communication about their strategy since last September? Time will tell.

This was flagged up on my LinkedIn account this morning. It is apparent that Alessandro Zamboni, has several side hustles in operation. Is he giving Syme the time and attention that is necessary to move it forward from its current low point? O

Is today’s event perhaps part of his convoluted plans?

“Today ROUTE Crypto Training is present at the event organized by Italian Insurtech Association - IIA and dedicated to AI, with a speech on the interactions between Blockchain and Artificial Intelligence, which will be the subject of one of the next Vertical Insights on our platforms.

Alessandro Zamboni, Antonio Scognamillo, Mariela Velicu”

There is something confusing here. The message states “we are pleased to note the presentation of our previously shared in vitro data …..”. When was this data shared previously?

“Novel therapeutics to prevent progression to severe COVID-19 remains a critical need so we are pleased to note the presentation of our previously shared in vitro data on SNG001’s effectiveness against various COVID-19 variants at the Microbiology Society Annual Conference earlier this week by UK Health Security Agency’s (UKHSA) Julia Tree. The presentation by the UKHSA underlines the potential for SNG001 for future pandemic preparedness. Further details on the abstract (A368) can be found here: https://lnkd.in/dXHqkfms”

Very recently, I was offered 7.34p for 30K shares, and 6.89p for ten times that amount. The quoted share price on my broker’s site is the same as last night’s closing value. The usual low level trading activity has resumed.

Consequently, yesterday’s flurry of trading was presumably created by the usual unsubstantiated social media hype? In the absence of news, the share price is likely to decline to the previous range? A storm in a teacup, nothing else IMO.

My complements to any traders, who bought low, and sold near yesterday’s cusp. Synairgen’s price may continue to be “manipulated” in this way, until the company shows its hand. This will benefit traders, but is of little use to LTIs, who are in search of more significant multi-bagging to recover some capital.

To take the underwater trope further. LTIs are unlikely to trade in case there is significant news and they are caught out without any shares. A bit like skinny dipping in the sea and the tide suddenly going out (Warren Buffet’s metaphor, not mine).

All IMHO. GLALTIs.

Thank you Tyke68 for sharing relevant information; my thanks also to others, who continuously do the same on this forum.

I have, foolishly as it turns out, held my IQAI investment, through thick and thin, for over two years. I have since realised that any company managed by Mr. Brown is optimal for traders rather than LTIs.

Nevertheless, in this case the products, and quality of technology, upon which the investment case rests is sound enough. The negative side is that competitors are presumably developing similar AI led scanning technology?

My aspiration rests on a major entity deciding to make an offer for the company. In my case 30p would be more than sufficient to realise a very good profit, although I appreciate that potentially, the value created by IB should command a significantly higher buyout offer.

GLALTIs.

Unfortunately, we cannot expect a sustainable share price re-rate in the absence of a significant update from Synairgen. Nor can the company be blamed for yesterday’s busy trading day, which resulted in a net share price increase.

The poster presentation, which may or may not have triggered the trading activity, was deeply “hidden”, and it took an impressive piece of research to unearth it. It wasn’t even presented by Synairgen, and there were no significant new findings included.

I am not trying to undervalue the quality of the information, and the testing was presumably commissioned for a good reason? My point is that yesterday’s activity has nothing whatsoever to do with my Synairgen investment, and I remain hopeful of positive news from the company during Q2.

GLALTIs.

This rise is welcome, but there isn't yet any indication of an underlying cause.

LTIs need a considerably greater increase than the current rise to recover their original investment. This will only happen with several significant updates from Synairgen.

I am looking at a time scale of years, if the company's strategy goes according to plan over the next three months or so.

Like everyone else's, my projections are meaningless until Synairgen informs us about the company's next steps.

GLALTIs.

Fruitsnveg.

Your earlier comment reminds me of Synairgen’s polite response when replying to investors’ queries over a year ago. Very little has happened since then, although we remain hopeful of a positive update.

No RNS then, but this wasn’t anticipated by the majority of investors.

I recall that when SNG001’s anti-viral response to in vitro testing was reported on 17 March, 2022, it was presented as a side hustle. The main issue then was an update on the Activ-2 trial. The former was a few sentences practically hidden in the RNS, viz.

“SNG001 has demonstrated in vitro antiviral activity against a broad range of respiratory viruses including SARS-CoV-2 and its variants including Delta and Omicron.”

Perhaps a summary of the latest presentation will be included with the anticipated company P2 trials update, when it emerges, presumably sometime during Q2?

For example Doc83, the latest one is:

08-Apr-24 08:54:58 5.7013 262,87 £14.99k

There is another of 250K shares, and a further two well in excess of 100K shares. Maybe this is meaningless, but an improvement on the recent meagre trading. Hopefully, more to come today? Time will tell!

Some chunky buys so far this morning, in the absence of anything from Synairgen.

There is nothing significant in this yet, but IMHO, we are due some news imminently should the declared H1 timeline turn out to be part of a coherent strategy.

You did well in finding that piece of news Brysoa. Akin to finding a needle in a haystack. Similar information from the company, about their contribution at industry events, has virtually ceased since the departure of Brooke Clarke. A case of from one extreme to the other, as we were receiving a considerable amount of superfluous information (for such a tiny company) via X/LinkedIn when Mrs. Clarke was in situ.

I remain optimistic despite the current total absence of communication from the company. In any case they are bound to tell us something, if only an update of the current financial position, before too long. I suspect that there may be rather more than that in the pipeline, given the time elapsed since the last communication.

GLALTIs.

Dippfs.

I learned of the departure of these executives from Spacman’s E.J. Thribb style “And so farewell …..” contributions on this forum. Subsequently, on checking the executives gallery on Synairgen’s website, which has now fallen to seven members.

I have no idea whether it is sufficient to infer from it the very interesting dialogue that has emerged here today. I wouldn’t rule anything out at this stage. It would explain the continued silence since last September.

As things stand, I remain in wait for news of the P2 trials, in line with the last company statement. A JV arrangement on top of this would be a very welcome development.

Jonnyboy33.

Your constant positivity in recent years on this forum has been truly appreciated, as it is this evening. I have been buoyed by your uplifting contributions on more than one occasion.

With my very best wishes for the best possible recovery to good health.

Like you, I remain optimistic that a bright light will soon start to shine at the end of what has been a long dark Synairgen-induced tunnel.

Warmest regards and take care, T_P.